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Abbreviated Infusion of Eptifibatide
After Successful Coronary Intervention
The BRIEF-PCI (Brief Infusion of Eptifibatide
Following Percutaneous Coronary Intervention) Randomized Trial
Anthony Y. Fung, MB, BS, FACC,* Jacqueline Saw, MD,* Andrew Starovoytov, MD,*
Cameron Densem, MD,* Percy Jokhi, MB, BCHIR, PHD,* Simon J. Walsh, MD,*
Rebecca S. Fox, PA, MSC,* Karin H. Humphries, MSC, MBA, DSC,† Eve Aymong, MD, MSC,†
Donald R. Ricci, MD, FACC,* John G. Webb, MD, FACC,† Jaap N. Hamburger, MD, PHD,*
Ronald G. Carere, MD, FACC,† Christopher E. Buller, MD, FACC*
Vancouver, British Columbia, Canada
Objectives The purpose of this study was to assess whether the early discontinuation of eptifibatide infusion in nonemer-
gent percutaneous coronary intervention (PCI) is associated with a higher frequency of periprocedural ischemic
myonecrosis.
Background The recommended regimen for eptifibatide is a double bolus followed by an infusion for 18 h. It is not known
whether the infusion can be shortened if the PCI is uncomplicated.
Methods We enrolled 624 patients with stable angina, acute coronary syndrome, or recent ST-segment elevation myocar-
dial infarction (48 h) who underwent successful coronary stenting and received eptifibatide. Patients were ran-
domly assigned to receive either an 18-h infusion or an abbreviated infusion of 2 h. The primary end point was
the incidence of periprocedural myonecrosis defined as troponin-I elevation 0.26 g/l. Secondary end points
included death, myocardial infarction, urgent target vessel revascularization at 30 days, and in-hospital major
bleeding using the REPLACE-2 (Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events) trial
criteria.
Results The incidence of periprocedural myonecrosis was 30.1% in the 2-h group versus 28.3% in the 18-h group
(mean difference: 1.8%; upper bound of 95% confidence interval: 7.8%; p  0.012 for noninferiority). The 30-
day incidence of myocardial infarction, death, and target vessel revascularization was similar in both groups
(p  NS). Major bleeding was less frequent in the 2-h group (1.0% vs. 4.2%, p  0.02).
Conclusions After uncomplicated PCI, eptifibatide infusion can be abbreviated safely to 2 h. It is not inferior to the standard
18-h infusion in preventing ischemic outcome, and it may be associated with less major bleeding. (Brief Infusion
of Eptifibatide Following Percutaneous Coronary Intervention [BRIEF PCI]; NCT00111566) (J Am Coll Cardiol
2009;53:837–45) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.060t
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tlycoprotein (GP) IIb/IIIa inhibitors are potent antago-
ists of platelet aggregation proven to be beneficial in
reventing periprocedural ischemic complications after PCI
ith or without routine stenting (1–3). The efficacy of
ptifibatide, a widely used cyclic heptapeptide belonging to
rom *Vancouver General Hospital and †St. Paul’s Hospital, Vancouver, British
olumbia, Canada. The study was funded in part by Vancouver General Hospital and
niversity of British Columbia Hospital Foundation, Cardiology Research Fund
11011500, 2006. The Division of Cardiology, Vancouver General Hospital, has
eceived unrestricted educational grants from Schering and Sanofi-Aventis
$10,000) for the UBC Interventional Cardiology Conference in Vancouver, 2006.s
Manuscript received April 15, 2008; revised manuscript received September 4,
008, accepted September 8, 2008.his class, was established in the placebo-controlled, ran-
omized ESPRIT (Enhanced Suppression of the Platelet
Ib/IIIa Receptor With Integrilin Therapy) trial (4,5). In
he ESPRIT study, high-dose eptifibatide administered in 2
oluses before PCI (180 g/kg each 10 min apart) followed
See page 846
y an extended infusion of 2.0 g/kg/min for 18 to 24 h
fter PCI resulted in a 35% reduction in death or myocardial
nfarction (MI) at 30 days, leading to early termination of
he trial. Although this regimen is now recommended
tandard care, the trial did not distinguish the contribution
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The BRIEF-PCI Trial March 10, 2009:837–45made by the boluses versus the
extended 18- to 24-h infusion.
The use of extended infusions
of eptifibatide after routine and
angiographically successful PCI
procedures has several potential
disadvantages. Prolonged and
uninterrupted exposure may in-
crease bleeding, particularly early
after arterial sheath removal. In-
deed, eptifibatide administered
in this manner increases bleed-
ing compared with heparin or
bivalirudin alone (4–6). Infu-
ions of 18-h duration also obligate overnight hospitaliza-
ion after PCI, and may raise practical issues related to
ost-PCI interhospital transport.
Clinical experience suggests that interventionalists can
ccurately identify patients at low risk for early ischemic
omplications upon conclusion of PCI procedures (7–10).
e hypothesized that an extended infusion of eptifibatide
n such patients is unnecessary for prevention of ischemic
omplications, and may lead to excess bleeding and cost.
e, therefore, performed a randomized trial comparing
bbreviated and extended infusions of eptifibatide after
ngiographically successful nonemergent stent-based PCI
rocedures.
ethods
he BRIEF-PCI (Brief Infusion of Intravenous Eptifi-
atide Following Successful Percutaneous Coronary Inter-
ention) trial was a randomized and double-blinded con-
rolled study comparing abbreviated infusion of eptifibatide
2-h group) to a standard 18-h infusion (18-h group). All
atients provided written informed consent before partici-
ation in the study. The study protocol was approved by the
niversity of British Columbia Research Ethics Board.
tudy population. Patients scheduled for nonemergent
CI, or referred for diagnostic catheterization and possible
CI, were potentially eligible if older than 18 years. Patients
ecame eligible for enrollment upon successful completion
f a PCI with stenting and primary use of eptifibatide.
atients were excluded for any of the following reasons:
ecent (48 h) ST-segment elevation MI; visible thrombus;
ivalirudin treatment; unprotected left main intervention;
se of ablative or thrombectomy devices; allergy or intoler-
nce to aspirin, thienopyridines, or eptifibatide; or unsatis-
actory PCI results. Unsatisfactory PCI was defined by any
f the following: final Thrombolysis In Myocardial Infarc-
ion (TIMI) flow grade 3; type B or worse dissection
ccording to the National Heart, Lung, and Blood Institute
lassification (11); definite thrombus or distal embolization;
n-stent residual stenosis 20% by visual estimate; loss of a
ajor side branch (estimated1.5-mm diameter); transient
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CK-MB  creatine kinase-
myocardial band
GP  glycoprotein
MI  myocardial infarction
NHLBI  National Heart,
Lung, and Blood Institute
PCI  percutaneous
coronary interventionessel closure or prolonged ischemia (15 min); hemody- eamic collapse; unsatisfactory deployment of a femoral
rtery closure device; or significant access site bleeding
uring PCI.
tudy protocol. Pre-treatment with aspirin was required.
or patients not receiving adequate clopidogrel pre-
reatment (defined as 75 mg/day 4 days, 300 mg loading
6 h, or 600 mg loading 2 h), clopidogrel 600 mg was
iven orally before or immediately after PCI in the labora-
ory (12–14). Either unfractionated heparin or enoxaparin
ere acceptable antithrombin agents. Heparin was admin-
stered as an intravenous bolus 50 to 70 IU/kg to achieve a
arget activated clotting time of 200 to 300 s. Its use after
CI was strongly discouraged. Intravenous eptifibatide (In-
egrilin, Schering, Kenilworth, New Jersey) was adminis-
ered before first balloon inflation as a bolus of 180 g/kg
wice, 10 min apart, followed by an intravenous infusion of
g/kg/min (dose reduction for patients with renal impair-
ent as per product monograph).
For patients who received adequate clopidogrel pre-
reatment, open-label eptifibatide infusions would be dis-
ontinued in the cardiac catheterization laboratory imme-
iately after PCI. After randomization using sealed
nvelopes in blocked sequences, such patients received
linded treatment with eptifibatide or placebo for 18 h. In
ontrast, patients who did not receive adequate clopidogrel
re-treatment were given oral clopidogrel loading 600 mg,
nd open-label eptifibatide infusion for 2 h. After random-
zation, these patients received blinded treatment with
ptifibatide or placebo for 16 h. Figure 1 shows the flow of
tudy participants.
Troponin-I, total creatine kinase, and creatine kinase-
yocardial band (CK-MB) were evaluated on samples
ollected immediately before the procedure, after PCI (6 to
h), and the next day (18 to 24 h). All blood samples were
orwarded to our center core laboratory for analysis. All
atients had electrocardiograms performed before the pro-
edure and before discharge. Patients were seen by research
oordinators during hospitalization, and telephone inter-
iews were conducted at 30 days.
tudy end points and definitions. The primary end point
as the incidence of ischemic myonecrosis within 24 h of
CI and before hospital discharge. Ischemic myonecrosis
as defined as the following: 1) elevated post-procedure
roponin-I level0.26 g/l if the baseline level was normal;
) if the baseline troponin-I level was elevated, then injury
as diagnosed when CK-MB was 3 times the upper limit
f normal; and 3) if both troponin-I and CK-MB were
levated at baseline, then injury was diagnosed if CK-MB
as 3 times the upper limit of normal and 50% higher
han baseline. Biomarkers were measured at the Core
hemistry Laboratory at the Vancouver General Hospital
nder the direction of Dr. M. Pudek. Troponin-I was
easured using the assay (Dimension RxL) manufactured
y Dade-Behring, Inc. (Mississauga, Ontario, Canada).
he cutoff value of 0.26 g/l was chosen as this value
xceeded 3 times the 99th percentile for a reference control
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March 10, 2009:837–45 The BRIEF-PCI Trialroup with a total test imprecision of 10% as recom-
ended by the Joint Committee of the European Society of
ardiology and American College of Cardiology in 2000
15). There were 2 secondary composite end points: 1)
eath, MI, or urgent target vessel revascularization (TVR)
t 30 days; and 2) death, MI, urgent TVR at 30 days, or
n-hospital major bleeding. The diagnosis of MI was made
ccording to the TIMI study criteria and on the basis of the
evelopment of new abnormal Q waves in 2 or more
ontiguous pre-cordial or adjacent limb leads, elevation of
K-MB levels 3 times the upper limit of normal, and if
he pre-PCI CK-MB level was higher than the upper limit
f normal, then an increase by at least 50% over the previous
Figure 1 Flow of Study Participants
See Methods section for explanation. CABG  coronary artery bypass graft surger
PCI  percutaneous coronary intervention; PTCA  percutaneous transluminal coralue (16). pBleeding end points were defined according to the
EPLACE-2 (Randomized Evaluation in PCI Linking
ngiomax to Reduced Clinical Events) criteria (6). Major
leeding included intracranial, intraocular, or retroperito-
eal hemorrhage, clinically overt blood loss resulting in a
ecrease in hemoglobin 3 g/dl, any decrease in hemoglo-
in 4 g/dl, or transfusion of at least 2 U of packed red
lood cells or whole blood. Minor bleeding included clini-
ally overt bleeding that did not meet criteria for major
leeding.
All major events were adjudicated and classified by an event
djudication committee blinded to the assigned treatments. An
ndependent data and safety monitoring committee received
ngioplasty.
y;
onary aeriodic reports blinded to assigned treatments.
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The BRIEF-PCI Trial March 10, 2009:837–45ample size and data analysis. The study was designed as
noninferiority trial of a brief infusion of eptifibatide. We
ssumed the incidence of ischemic myocardial injury within
he first 24 h to be 50% in the 18-h group. The upper
argin for the difference between the 18-h group and the
2-h group was set at 10%. Setting power at 80% and a
-sided alpha at 0.05, a sample size of 620 was obtained
sing nQUERY, version 5.0 (Statistical Solutions, Saugus,
assachusetts). To account for the randomization with
equence blocks of 6, we further expanded randomization to
nclude 624 patients.
Descriptive data are presented as mean (SD) or as
roportions (%). Categorical data were compared with the
hi-square tests. The primary and secondary end points
ere analyzed using the test statistic described for a 1-sided
ull hypothesis that 18-h infusion of eptifibatide is superior
o 2-h infusion of eptifibatide (17). Mean differences and
he respective 1-sided, upper bound of the 95% confidence
nterval were computed for 3 key subgroups including
iabetic patients treated with insulin or oral agents; ade-
uate clopidogrel pre-treatment; and presentation with
CS or recent MI. The presence of effect modification was
ssessed using logistic regression modeling of the interac-
ion between the subgroup of interest and the treatment
odality on outcome.
All analyses were conducted according to the intention-
o-treat principle, and p  0.05 was designated as statisti-
ally significant. Statistical tests were performed using SPSS
oftware, version 13 (SPSS Inc., Chicago, Illinois) and R
ersions 2.4.0 (The R Foundation for Statistical Comput-
ng, Vienna, Austria).
esults
he study was conducted at 2 University of British Colum-
ia teaching hospitals (Vancouver General Hospital and St.
aul’s Hospital) in Vancouver, British Columbia, Canada,
ith recruitment from December 2004 through July 2007.
igure 1 shows the flow of study participants. There were no
ignificant differences between treatment groups in baseline
haracteristics (Table 1). Approximately one-half of the
opulation presented with acute coronary syndrome (ACS)
r had a recent (48 h) ST-segment elevation infarction.
ost patients with ACS presentation had elevated bio-
arkers during the hospitalization (80%). No significant
ifferences in procedural characteristics existed between the
treatment groups (Table 2).
The primary end point of ischemic myocardial injury
ithin 24 h after PCI was similar in both groups (30.1% in
he 2-h group vs. 28.3% in the 18-h group; mean
ifference: 1.8%; upper bound of 95% confidence interval:
.8%; p  0.012 for noninferiority). Among key patient
ubgroups, neither diabetes mellitus (treated with insulin or
ral agents), clopidogrel pre-treatment, nor presentation
ith ACS or recent MI showed a significant interaction
ith assigned treatments (Fig. 2). The primary end point inalysis was repeated using the “per-protocol” principle,
fter excluding all the patients who had the eptifibatide/
lacebo infusion terminated prematurely (19 patients in the
8-h group and 20 patients in the 2-h group). Again,
here was no significant difference between the 2 groups
31.4% in the2-h group vs. 29.4% in the 18-h group, p
.001 for noninferiority).
Clinical follow-up at 30 days was 100%. No death, stent
hrombosis, or Q-wave MI occurred in either group (Table 3).
on–Q-wave MI occurred with similar frequency in both
roups (4.8% in the2-h group vs. 4.5% in the 18-h group,
 1.0). Two patients in the 2-h group and 3 patients in
he 18-h group had post-procedure non–Q-wave MI and
nderwent urgent TVR with repeat PCI (1 patient on the
ame admission and 4 patients after readmission within 30
ays).
In-hospital bleeding was adjudicated to be major on the
asis of the REPLACE-2 study criteria in a total of 16
atients, 3 in the 2-h group and 13 in the 18-h group
1.0% vs. 4.2%, p  0.02) (Table 4). One patient had upper
astrointestinal bleeding, and 15 patients had bleeding at
ascular access sites (4 patients with false aneurysms that
equired surgical repair or ultrasound-guided thrombin
haracteristics of Study Patients
Table 1 Characteristics of Study Patients
<2-h Group
(n  312)
18-h Group
(n  312)
Age, mean  SD, yrs 62.1 10.3 63.1 9.9
Male, % (n) 80.1 (250) 84.0 (262)
Caucasian, % (n) 89.1 (278) 91.6 (286)
Prior PCI, % (n) 24.0 (75) 24.7 (77)
Prior CABG, % (n) 6.1 (19) 7.1 (22)
Prior MI, % (n) 32.4 (101) 30.1 (94)
Diabetes mellitus (on insulin or oral agents), % (n) 12.2 (38) 15.4 (48)
Hypertension, % (n) 63.8 (199) 67.6 (211)
Hyperlipidemia, % (n) 76.6 (239) 82.1 (256)
Active smoker (within 1 month) , % (n) 20.8 (65) 17.0 (53)
Body mass index, mean  SD, kg/m2 28.1 5.1 28.7 4.7
Clinical presentation, % (n)
Stable angina 46.5 (145) 51.3 (160)
ACS 38.8 (121) 34.6 (108)
STEMI 48 h 14.7 (46) 14.1 (44)
Elevated biomarkers with ACS, % 80.2 80.9
Pre-procedural medication, % (n)
Aspirin 100 (312) 100 (312)
Adequate clopidogrel pre-treatment 70.8 (221) 65.7 (205)
Calcium-channel blockers 21.2 (66) 19.6 (61)
ACE inhibitors or ARB 66.7 (208) 69.6 (217)
Beta-blockers 83.7 (261) 88.5 (276)
Statins 79.5 (248) 84.8 (264)
Pre-procedural renal insufficiency, ml/min, % (n)
CrCl 60 but 30 12.8 (39) 17.3 (52)
CrCl 30 0 (0) 0.7 (2)
CE  angiotensin-converting enzyme; ACS  acute coronary syndrome; ARB  angiotensin
eceptor blocker; CABG  coronary artery bypass graft surgery; CrCl  creatinine clearance; MI 
yocardial infarction; PCI  percutaneous coronary intervention; STEMI  ST-segment elevation
yocardial infarction.njections, 1 patient with retroperitoneal bleeding treated
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DES  drug eluting stent(s).
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March 10, 2009:837–45 The BRIEF-PCI Trialonservatively, and 10 patients with hematomas associated
ith a hemoglobin drop 3 g/dl). Among the 624 patients
andomized, 29 patients had early termination of the epti-
batide/placebo infusions due to clinically overt bleeding
omplications (20 in the 2-h group and 19 in the 18-h
roup); and transfusion of blood products was given to 2
atients because of access site bleeding (both in the 2-h
roup). Unblinding of the study drug assignment was never
equired.
Pre-defined secondary end points included the 30-day
omposite triple end points of death, MI, and urgent TVR.
he event rates were similar in the 2 groups (2-h group
.8% vs. 18-h group 4.5%, p  NS). Pre-defined secondary
uadruple end points included the triple end points plus
EPLACE-2 study criterion of major bleeding, and again,
he 2 groups were not statistically different (2-h group
.4% vs. 18-h group 8.7%, p  NS).
iscussion
ur data show that post-procedure eptifibatide infusion can
e safely abbreviated to 2 h after successful and uncom-
licated PCI performed with heparin and double-bolus
ptifibatide. In comparison with the standard 18-h infusion,
he abbreviated regimen was not inferior in preventing
ps
ural myonecrosis
upper confidence limit.rocedural Characteristics
Table 2 Procedural Characteristics
<2-h Group
(n  312)
18-h Group
(n  312)
Total eptifibatide infusion time, mean  SD, h 1.4 0.78 16.8 3.4
Femoral access, % (n) 97.1 (303) 95.5 (298)
Sheath size, % (n)
6-F 87.8 (274) 88.1 (275)
7-F 10.3 (32) 10.6 (33)
Extent of disease, % (n)
Single vessel 48.1 (150) 48.7 (152)
Multivessel 51.9 (162) 51.3 (160)
Target vessel, % (n)
Left anterior descending artery 47.8 (149) 45.5 (142)
Left circumflex artery 31.7 (99) 31.4 (98)
Right coronary artery 37.5 (117) 39.1 (122)
Ramus intermedius artery 1.6 (5) 1.9 (6)
Bypass graft 1.3 (4) 0.6 (2)
Number of vessels treated, mean  SD 1.23 0.4 1.22 0.4
Total stent length, mm 29.4 18 28.6 17
% of DES used 31.9 35.4
Worst lesion AHA type B2 or C*, % (n) 62.7 (138) 62.3 (134)
Femoral closure device, % (n) 25.6 (80) 25.3 (79)
Defined according to lesion classification of American College of Cardiology/American HeartFigure 2 <2-h Versus 18-h Eptifibatide Infusion in Selected Subgrou
Frequency and effects of 2-h (2H) versus 18-h (18H) eptifibatide infusion on periproced
in selected subgroups. ACS  acute coronary syndrome; PreRx  pre-treatment; UCL 
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The BRIEF-PCI Trial March 10, 2009:837–45schemic events, and resulted in less post-procedural major
leeding.
We believe our results are applicable to most candidates
or contemporary PCI with stenting. Patients with stable
ngina and those hospitalized with ACS or recovering from
T-segment elevation MI were enrolled, and these 2 groups
ere equally represented (50% each). However, patients
ith high thrombus burden (e.g., acute myocardial infarc-
ion of 48 h, or obvious filling defects seen on angiogra-
hy) were excluded because such patients seemed likely to
enefit from a more prolonged infusion. Among 711 con-
enting patients who were candidates for inclusion before
CI and received primary eptifibatide in the cardiac cathe-
erization laboratory, only 80 (11%) were excluded before
nrollment.
We specified troponin-I release as the marker of ischemic
yonecrosis (primary end point). This very sensitive bio-
arker was selected to minimize the chance of failing to
etect a low intensity signal of harm attributable to abbre-
iating eptifibatide infusions. Although troponin release
fter PCI does not always predict adverse long-term out-
ome (18,19), studies with magnetic resonance imaging
ave confirmed that minor elevation of troponin after PCI
s due to MI. Moreover, a positive quantitative relationship
etween the magnitude of troponin release and the extent of
nfarction has been demonstrated (20,21).
The ISAR-REACT (Intracoronary Stenting and Anti-
hrombotic Regimen: Rapid Early Action for Coronary
reatment) trial showed that GP IIb/IIIa inhibition is not
eneficial in patients identified as low risk before PCI,
rovided patients are pre-treated with high-dose clopidogrel
600 mg orally given 2 h) and aspirin (22). This approach
ay not be applicable to many patients in our study because
0% had recent ST-segment elevation MI or ACS (80%
ith elevated biomarkers). Indeed, in the ISAR-REACT-2
rial, GP IIb/IIIa inhibition was superior to placebo in the
ubgroup of patients with ACS and troponin elevation (23).
nalysis of the subgroup of patients with recent ST-
egment elevation MI or ACS in our study showed that the
bbreviated eptifibatide regimen provided results similar to
hose of the standard 18-h infusion arm, and there was no
nteraction between the mode of presentation and treatment
schemic and Bleeding Incidents at 30 Days
Table 3 Ischemic and Bleeding Incidents at 30 Days
Event <2-h Group (n  312)
Death, MI, or urgent TVR, % (n) 4.8 (15)
Death, MI, urgent TVR, or major bleeding, % (n) 5.4 (17)
Death, % (n) 0 (0)
Stroke, % (n) 0 (0)
MI (Q-wave or non–Q-wave), % (n) 4.8 (15)
Q-wave MI, % (n) 0 (0)
Urgent TVR (PCI or CABG), % (n) 0.6 (2)
CABG, % (n) 0 (0)
VR  target vessel revascularization; UCL  upper confidence limit; other abbreviations as in Tassignments (Fig. 2). Thus, while the use of GP IIb/IIIa anhibitors may be beneficial in ACS, we believe the infusion
an be abbreviated for appropriate patients after uncompli-
ated stenting. The ISAR-REACT-2 trial also emphasized
he importance of clopidogrel pre-treatment (600 mg 2 h
efore PCI). However, clopidogrel is frequently withheld in
d hoc PCI because of the potential for bleeding should the
atient require early CABG (24). In our study, 31% of our
atients did not receive adequate pre-treatment with clopi-
ogrel. Current guidelines support the use of GP IIb/IIIa
nhibitors for such patients (25). Our study results were
onsistent with noninferiority for the abbreviated eptifi-
atide infusion in this common and important subgroup.
mong the 624 patients enrolled in our study, only 165
atients (26.4%) were “ISAR-REACT eligible” (Fig. 3).
ess major bleeding. In the ESPRIT trial, patients treated
ith eptifibatide were more likely to have major bleeding
han the placebo group (4). Data from the NHLBI dynamic
egistry showed GP IIb/IIIa inhibition in PCI was associ-
ted with a higher likelihood of developing access site
ematomas that required blood transfusion (26). The
EPLACE-2 study showed that there was more major
leeding with heparin plus GP IIb/IIIa blockade than with
he bivalirudin plus provisional GP IIb/IIIa blockade (9.8%
s. 3.8%, p  0.001) (6). Our study showed that shortening
he infusion of eptifibatide provides an alternative means of
educed bleeding without eliminating the role of GP IIb/
IIa inhibition altogether.
Bertrand et al. (27) have previously tested the safety of
runcating the administration of a GP IIb/IIIa inhibitor
uring PCI. They randomly allocated 1,005 patients after a
olus of abciximab and uncomplicated transradial PCI to
ither same-day discharge and no abciximab infusion, or to
vernight hospitalization and a standard 12-h abciximab
nfusion. They found that same-day discharge and abcix-
mab bolus only was not inferior to the standard overnight
ospitalization and bolus plus 12-h infusion, with respect to
he 30-day incidence of death, MI, urgent revascularization,
ajor bleeding, repeat hospitalization, access site complica-
ions, and severe thrombocytopenia. Unlike our study, they
sed abciximab instead of eptifibatide; they measured
roponin-T instead of troponin-I; and they used the trans-
adial approach (100%) whereas we used the transfemoral
18-h Group (n  312) Difference (%) (<2-h–18-h) 95% UCL
4.5 (14) 0.3 3.1%
8.7 (27) 3.2 0.2%
0 (0) — —
0 (0) — —
4.5 (14) 0.3 3.1%
0 (0) — —
1.0 (3) 0.3 1.0%
0 (0) — —pproach (96%). Abciximab has prolonged antiplatelet
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March 10, 2009:837–45 The BRIEF-PCI Trialffects even after a single bolus, whereas eptifibatide has a
horter duration of action (28,29). Abciximab bolus ac-
ounts for 75% of total dose, and our abbreviated regimen
as37% of the dose of the standard regimen. Both studies
howed low clinical ischemic events and similar effectiveness
n preventing troponin release. The major bleeding rate was
ery low in the study by Bertrand et al. (27), at 0.5%,
ttributed to the use of transradial approach. On the
ontrary, the EPIC (Evaluation of c7E3 for the prevention
f Ischemic Complications) trial showed that abciximab
olus followed by a 12-h infusion was superior to the
olus-only regimen, with a 35% reduction in the rate of
eath, MI, unplanned revascularization, unplanned implan-
ation of a coronary stent, or insertion of an intra-aortic
alloon pump for refractory ischemia at 30 days (p 
.008), compared with only a 10% nonsignificant reduction
n patients who received the abciximab bolus only. How-
ver, the higher event rate was mostly driven by urgent
epeat revascularization (3.8% bolus only, 0.8% bolus plus
nfusion, p  0.001), which could be accounted for by the
ack of stent utilization (1% of patients). Furthermore, the
PIC study enrolled high-risk patients with evolving MI,
efractory unstable angina, or unfavorable clinical or angio-
raphic features. These 2 key features may explain the
ecessity of prolonged platelet inhibition in the EPIC study,
nlike the study by Bertrand et al. (27) and our study. In the
tent era, the ESPRIT trial studied lower-risk patients and
howed that eptifibatide boluses followed by an infusion for
8 to 24 h was superior to placebo, resulting in a 35%
eduction in death or MI at 30 days. However, the ESPRIT
rial did not study the bolus-only or the short infusion
pproaches.
uggested use of eptifibatide in contemporary nonemer-
ent PCI. One feasible approach is to risk-stratify patients
n the basis of clinical presentation (stable angina vs. ACS),
nd to reserve eptifibatide for patients with ACS. Some
perators may also choose to use eptifibatide if the coronary
ntervention is complex (e.g., bifurcation lesions, long le-
ions, small vessels, large plaque burden, diabetic, and so
orth). However, risk stratification is a dynamic process, and
ost-PCI Bleeding Events,ransfusion, and Thrombocytopenia
Table 4 Post-PCI Bleeding Events,Transfusion, and Thrombocytopenia
<2-h Group
(n  312)
18-h Group
(n  312) p Value
Major bleeding, % (n) 1.0 (3)* 4.2 (13)† 0.02
Minor bleeding, % (n) 17.6 (55) 21.2 (66) 0.31
Transfusion of blood
products, % (n)
0.6 (2) 0 (0) 0.49
Thrombocytopenia
100  109/l, % (n)
0.3 (1) 0.3 (1) 1.0
The 3 major bleedings included 1 upper gastrointestinal tract bleeding, 1 pseudoaneurysms
equiring surgical repair, 1 hematoma10 cm with hemoglobin (Hb) drop30 g/l. †The 13 major
leedings included 1 retroperitoneal bleeding, 3 pseudoaneurysms requiring surgical repair, 1
pistaxis and hematoma 10 cm with Hb drop 30 g/l, 8 hematomas 5 cm with Hb drop
30 g/l.
PCI  percutaneous coronary intervention.t may be easier to predict short-term outcome after com-letion of the PCI procedures. Previous studies have shown
hat while the prophylactic use of GP IIb/IIIa inhibitors is
ffective, its use as a rescue agent is much less so (4,30).
hus, our study supports discontinuation of the eptifibatide
nfusion early if the PCI proves successful and uncompli-
ated. The pharmaceutical cost for a full course of eptifi-
atide is $450 U.S. for an average-weight patient in our
ospital. With the abbreviated regimen, most patients can
e treated with approximately one-third of the total dose,
nd there will be cost saving. Bleeding risk can also be
inimized with the abbreviated regimen. Another reason-
ble approach is to use bivalirudin for most cases.
tudy limitations. A key entry criterion of our study is the
successful” completion of an “uncomplicated” PCI. The
perator should be certain that the angiographic result is
atisfactory without complications that necessitate pro-
onged GP IIb/IIIa inhibition such as the presence of
ntracoronary thrombus or “unsealed” dissection. We did
ot study acutely ill patients, such as those with acute MI,
efractory ischemia, or hemodynamic compromise. All of
ur patients with ACS were stabilized before inclusion.
hus, our results may not be applicable to ACS patients
ho underwent very early intervention (within hours) or
hose with ongoing chest pain. The incidence of ischemic
yonecrosis after PCI (18-h group, 28.3%) was lower than
nticipated when we wrote the protocol (50%) (31,32) and
as likely related to the fact that patients with suboptimal
CI results were not enrolled. As a result, our study lacked
ower to detect small differences between the 2 treatment
roups. Although the pre-specified 10% upper margin to
enote noninferiority was not exceeded, results should be
Figure 3 Proportion of Patients Potentially Eligible
for Entry Into ISAR-REACT Study (n  624)
ACS  acute coronary syndrome; ISAR-REACT  Intracoronary Stenting and
Antithrombotic Regimen: Rapid Early Action for Coronary Treatment trial;
STEMI  ST-segment elevation myocardial infarction.
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The BRIEF-PCI Trial March 10, 2009:837–45nterpreted with some reservation in view of the lower event
ate. Post hoc analysis showed the upper bound of the 95%
onfidence interval for the primary end point to be 7.8%,
hich we believe is an acceptable clinical boundary. The
bsolute difference between the 2 treatment groups using
he troponin I criteria was modest at 1.8%, and it was also
mall using the more stringent CK-MB criteria (3 times
he upper limit of normal) at 0.3%.
onclusions
fter successful and uncomplicated nonemergent PCI with
tenting, the post-procedural infusion of eptifibatide can be
afely abbreviated to 2 h, and it is not inferior to the
tandard 18-h infusion in preventing periprocedural isch-
mic events. The abbreviated regimen will reduce pharma-
eutical cost and also reduce the likelihood of post-
rocedural major bleeding.
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PPENDIX
he BRIEF-PCI study was organized as follows: Steering
ommittee: A. Fung, Principal Investigator, E. Aymong, C.
uller, R. Fox, K. Humphries, J. Saw, and J. Webb (Vancou-
er, British Columbia). Dr. Fung has full access to all of the
ata in the study and takes responsibility for the integrity of the
ata and the accuracy of the data analysis. Data and Safety
onitoring Board: W. D. Weaver, Chair (Detroit, Michigan),
. Dixon (Royal Oak, Michigan), and K. Ramanathan (Van-
ouver, British Columbia). Clinical Event Adjudication Com-
ittee: G. Wong (Vancouver, British Columbia). Cardiac
iomarkers Core Laboratory: M. Pudek (Vancouver, British
olumbia).
